1. Home
  2. MVIS vs DCTH Comparison

MVIS vs DCTH Comparison

Compare MVIS & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MicroVision Inc.

MVIS

MicroVision Inc.

HOLD

Current Price

$0.65

Market Cap

271.6M

Sector

Technology

ML Signal

HOLD

Logo Delcath Systems Inc.

DCTH

Delcath Systems Inc.

HOLD

Current Price

$9.54

Market Cap

311.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MVIS
DCTH
Founded
1993
1988
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Medical/Dental Instruments
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
271.6M
311.7M
IPO Year
2010
2015

Fundamental Metrics

Financial Performance
Metric
MVIS
DCTH
Price
$0.65
$9.54
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
4
Target Price
$2.25
$22.00
AVG Volume (30 Days)
7.4M
335.0K
Earning Date
03-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
23.91
107.53
EPS
N/A
0.07
Revenue
$664,000.00
N/A
Revenue This Year
$529.06
$24.54
Revenue Next Year
$168.46
$33.15
P/E Ratio
N/A
$132.57
Revenue Growth
N/A
N/A
52 Week Low
$0.51
$8.12
52 Week High
$1.73
$18.23

Technical Indicators

Market Signals
Indicator
MVIS
DCTH
Relative Strength Index (RSI) 47.49 53.64
Support Level $0.51 $8.90
Resistance Level $0.73 $10.17
Average True Range (ATR) 0.06 0.32
MACD 0.01 0.02
Stochastic Oscillator 58.06 61.67

Price Performance

Historical Comparison
MVIS
DCTH

About MVIS MicroVision Inc.

Microvision Inc is engaged in developing a lidar sensor to be used in automotive safety and autonomous driving applications. Its lidar sensor uses laser beam scanning (LBS) technology, which is based on systems that include micro-electrical mechanical systems (MEMS), laser diodes, opto-mechanics, electronics, algorithms, and software. The company has also developed solutions for Augmented Reality, Interactive Displays, and Consumer Lidars.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. The company is focused on the treatment of primary and metastatic liver cancers. The firm's product include Melphalan Hydrochloride, Hepzato for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: